Acute Coronary Syndrome

Cardiovascular·MeSH: Acute Coronary Syndrome

12 drugs in development·9 companies·13 clinical trials

Drug Pipeline by Phase

Approved(7)

Drug	Company
clopidogrel bi	DR REDDYS LABORATORIES LTD (RDY)
clopidogrel bi	Teva Pharmaceutical Industries Limited (TEVA)
prasugrel	Mylan II B.V. (MYL)
ticagrelor	Mylan II B.V. (MYL)
ticagrelor	Amneal Pharmaceuticals, Inc. (AMRX)
ticagrelor	DR REDDYS LABORATORIES LTD (RDY)
tirofiban	NEXUS BIOPHARMA INC (NEXS)

Phase 3(2)

Drug	Company
milvexian	GH Research PLC (GHRS)
pelacarsen	Novartis AG (NVS)

Phase 1(1)

Drug	Company
aem-28	Capstone Holding Corp. (CAPS)

Preclinical(1)

Drug	Company
aem-28-08	Capstone Holding Corp. (CAPS)

Phase 4(1)

Drug	Company
Colchicine 0.6 mg	Cidara Therapeutics, Inc. (CDTX)

BioSniper tracks 12 drugs in development for Acute Coronary Syndrome across 9 companies.

There are 13 clinical trials targeting Acute Coronary Syndrome tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.